A proposed policy move would ban or limit China clinical trial data in a way that reflects increased congressional concern about competition from China, according to reporting. The measure signals Washington’s willingness to tighten how sponsors use foreign clinical evidence. Even if adoption remains unlikely, the analysis describes strong legislative interest and a broader shift in how regulators and policymakers evaluate data provenance, including potential impacts on development timelines and evidence packages. For biotech companies with China-based trials, the proposal underscores the need to plan for alternative submission strategies and potential reanalysis if policy conditions tighten.